Real world embedding
close
프로필 배경
프로필 로고

Real world embedding

  • 분류 전체보기 (422)
    • devOps (5)
    • Pharmacology (411)
      • News (8)
      • BS (402)
  • 홈
  • BS
  • devOps

Publication of AKS-452 Phase II Vaccine Study Results in Nature Vaccines Highlights Advancements of Akston Biosciences' Ambifect® Fc-fusion Platform

Publication of AKS-452 Phase II Vaccine Study Results in Nature Vaccines Overview Company: Akston Biosciences Indication: SARS-CoV-2 Vaccination Drug: AKS-452 Trial Phase: Phase 2 NCT ID: N/A Study Results Akston Biosciences has published the results of their Phase II clinical trial for the AKS-452 vaccine in Nature Vaccines. This study, conducted in the Netherlands, aimed to boost the immune re..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

Harvard Gastroenterology Specialist Dr. Hamed Khalili Appointed to Vivante Health Clinical Advisory Board for Inflammatory Bowel Disease Research

Harvard Gastroenterology Specialist Dr. Hamed Khalili Joins Vivante Health Advisory Board Overview Company: Vivante Health Indication: Inflammatory Bowel Diseases Drug: N/A Trial Phase: N/A NCT ID: N/A Details Vivante Health has appointed Dr. Hamed Khalili to its Clinical Advisory Board to advance research in inflammatory bowel diseases. Dr. Khalili is a respected gastroenterologist at Massachus..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

Initiation of KOMET-008 Phase 1 Clinical Trial by Kura Oncology with Ziftomenib and Standard Care Combinations for Acute Myeloid Leukemia Patients with Specific Genetic Alterations

Initiation of KOMET-008 Phase 1 Clinical Trial by Kura Oncology with Ziftomenib and Standard Care Combinations for Acute Myeloid Leukemia Patients with Specific Genetic Alterations Overview Company: Kura Oncology, Inc. Indication: Acute Myeloid Leukemia (AML) Drug: Ziftomenib Trial Phase: Phase 1 NCT ID: NCT06001788 Introduction On February 26, 2024, Kura Oncology, Inc., a company at the forefro..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

MoonLake Immunotherapeutics Receives Unanimous Support for Phase 3 Trial of Sonelokimab in Hidradenitis Suppurativa from FDA and EMA

MoonLake Immunotherapeutics Receives Unanimous Support for Phase 3 Trial of Sonelokimab in Hidradenitis Suppurativa from FDA and EMA Company: MoonLake Immunotherapeutics Indication: Hidradenitis Suppurativa (HS) Drug: Sonelokimab (SLK) Trial Phase: Phase 3 NCT ID: NCT05322473 Overview MoonLake Immunotherapeutics, a clinically-focused biopharmaceutical company, has announced a significant milesto..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

BioCity Biopharma Completes Enrollment for IgA Nephropathy Cohort in Phase II Trial of SC0062, Aiming to Target CKD and Proteinuria

BioCity Biopharma Completes Enrollment for IgA Nephropathy Cohort in Phase II Trial of SC0062 Company: BioCity Biopharma Indication: IgA nephropathy (IgAN), chronic kidney disease (CKD), diabetic kidney disease (DKD) Drug: SC0062 Trial Phase: Phase 2 NCT ID: Not provided Overview BioCity Biopharma has announced the successful completion of patient enrollment for the IgA nephropathy (IgAN) cohort..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

Enhanced Risk Stratification in Stage I Melanoma Patients Achieved Using DecisionDx-Melanoma Test Over Traditional AJCC8 Methodology

Enhanced Risk Stratification in Stage I Melanoma Patients Using DecisionDx-Melanoma Overview Company: Castle Biosciences, Inc. Indication: Stage I Cutaneous Melanoma (CM) Drug/test: DecisionDx-Melanoma Test Trial Phase: Not Applicable NCT ID: Not Available Background Castle Biosciences, Inc. announced on February 26, 2024, a significant enhancement in risk stratification for Stage I Cutaneous Me..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

Preliminary Results Display Full Tumor Eradication in Non-surgical Breast Cancer Patients Using IceCure's ProSense® Cryoablation Therapy

Preliminary Results Display Full Tumor Eradication in Non-surgical Breast Cancer Patients Using IceCure's ProSense® Cryoablation Therapy Overview Company: IceCure Medical Ltd. Indication: Early-Stage Breast Cancer Drug/Treatment: ProSense® System Trial Phase: Not applicable NCT ID: Not available Study Summary In a groundbreaking study led by Dr. Federica di Naro at Azienda Ospedaliero-Universita..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

NewBiologix Engages with Florabio to Transform Gene Therapy Manufacturing through Advanced HEK293 Cell Line Engineering

NewBiologix Engages with Florabio to Transform Gene Therapy Manufacturing through Advanced HEK293 Cell Line Engineering Company: NewBiologix SA Indication: Not Applicable Drug: Recombinant adeno-associated virus (rAAV) vectors Trial Phase: Not Applicable NCT ID: Not Available Overview On February 27, 2024, NewBiologix SA, a biotech firm based in Lausanne, Switzerland, announced a strategic partn..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

Akili and Shionogi Declare Success in Phase 3 Clinical Trial for EndeavorRx as ADHD Treatment for Japanese Children

Akili and Shionogi Declare Success in Phase 3 Clinical Trial for EndeavorRx as ADHD Treatment for Japanese Children Overview Company: Akili, Inc. & Shionogi & Co. Ltd Indication: Pediatric ADHD Drug: SDT-001 (localized version of AKL-T01 / EndeavorRx) Trial Phase: Phase 3 NCT ID: N/A Akili, Inc., in collaboration with Shionogi & Co. Ltd, announced the successful completion of a Phase 3 clinical ..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

Bitterroot Bio and Biotheus Forge Partnership for Bispecific Protein Development in Cardiovascular Immunotherapy

Bitterroot Bio and Biotheus Forge Partnership for Bispecific Protein Development in Cardiovascular Immunotherapy Overview Company: Bitterroot Bio; Biotheus Indication: Cardiovascular diseases Drug: N/A Trial Phase: N/A NCT ID: N/A Details In a significant stride within the field of cardio-immunology, Bitterroot Bio and Biotheus have publicly announced the establishment of a multi-year research c..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms
  • navigate_before
  • 1
  • 2
  • 3
  • 4
  • ···
  • 41
  • navigate_next
공지사항
  • 데이터 요청 관련 문의
전체 카테고리
  • 분류 전체보기 (422)
    • devOps (5)
    • Pharmacology (411)
      • News (8)
      • BS (402)
최근 글
인기 글
최근 댓글
태그
  • #cancer
  • #Trial
  • #astrazeneca
  • #Phase 3
  • #Study
  • #N/A
  • #FDA approval
  • #Safety
  • #fda
  • #Clinical Trial
전체 방문자
오늘
어제
전체
Copyright © 쭈미로운 생활 All rights reserved.
Designed by JJuum

티스토리툴바